UNSPSC 51362401: Ramelteon

This classification denotes a cns stimulant with the molecular formula C16H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 901AS54I69, chemically known as (s)-n-(2-(1,6,7,8-tetrahydro-2h-indeno-(5,4)furan-8-yl)ethyl)propionamide but generally known as ramelteon, which bears US NIH Compound Identifier 208902. European Medicines Agency schedules Ramelteon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21315.

UNSPSC 51362401 Ramelteon is a Commodity code that nominally covers a specific insomnia medication, but recent state and local procurement activity under this code shows minimal alignment with the narrow pharmaceutical scope. State and local governments soliciting under this code are primarily purchasing broader pharmacy benefit products and services, including naloxone and drug deactivation systems, generic pharmaceuticals distributed through cooperative purchasing agreements, and direct-to-manufacturer prescription program infrastructure. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The work involves procurement of finished pharmaceutical products for community health initiatives, negotiation of direct manufacturer contracts to optimize cost and supply chain efficiency, and establishment of multi-vendor distribution agreements for generic and over-the-counter medications across state and local health systems.

Recent opportunities reflect activity concentrated in the South and Upper Midwest. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with a two-year initial term and one-year renewal option; the Texas HHS Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to bypass traditional pharmacy benefit managers and wholesalers; and the Minnesota Department of Administration's Office of State Procurement (administering the multistate MMCAP cooperative) issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic and OTC pharmaceuticals distributed through three authorized wholesalers to participating state and local government facilities across the Midwest and Northwest. The MMCAP procurement weighted price competitiveness at 75 percent of evaluation and required vendors to maintain contractual relationships with at least two of three named wholesalers, pay a 3 percent administrative fee, and comply with cGMP and Drug Supply Chain Security Act standards. The code shows limited recent activity specifically for ramelteon; procurement activity tagged to this code is driven by broader state and local pharmaceutical sourcing, cooperative purchasing, and supply-chain optimization initiatives rather than demand for the named medication.